ProCE Banner Activity

Phase II Trial of Venetoclax + Ibrutinib in Patients With Relapsed/Refractory or Untreated High-Risk CLL

Slideset Download
Conference Coverage
In this interim analysis, venetoclax plus ibrutinib combination therapy achieved high response rates in patients with CLL, with many patients achieving MRD-negative bone marrow.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology